- Analyst firm Needham set a new price target of $34 for Nurix Therapeutics, indicating an 86% potential upside.
- Nurix Therapeutics secured a significant partnership with Roche, valued at up to $2.3 billion, for its BTK-degrading drug, Bexobrutideg.
- The deal includes an upfront payment of $700 million to Nurix, with shared development costs and profit/loss in the U.S.
Nurix Therapeutics (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company. It focuses on developing a class of medicines that control protein levels in cells. The company’s main goal is to use these drugs to treat cancer and other serious diseases.
On June 8, 2026, analyst firm Needham raised its price target for Nurix to $34. At the time of the announcement, the stock was trading at $15.89. This new price target represents a potential upside of approximately 86% from the price when the target was set.
This optimism follows a major announcement. As highlighted by Investors.com, Nurix entered a deal worth up to $2.3 billion with Swiss drugmaker Roche. The agreement is centered on Nurix’s BTK-degrading drug, Bexobrutideg, which is being developed to treat blood cancer and other conditions.
Under the terms of the deal, Nurix receives an upfront cash payment of $700 million. The Wall Street Journal notes that Roche will cover 60% of the drug’s development costs, with Nurix responsible for the remaining 40%. The two companies will share profits and losses equally in the United States.
The market reacted strongly to the news, with the stock price surging past its 50-day moving average. Shares traded at $15.66, an increase of $1.02 or 6.97% for the day. The trading volume was notably high at over 15.4 million shares.
